This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Samyang Biopharmaceuticals Corporation
ClinicalTrials.gov Identifier:
NCT01103791
First received: April 5, 2010
Last updated: May 2, 2017
Last verified: May 2017
April 5, 2010
May 2, 2017
April 2010
September 2011   (Final data collection date for primary outcome measure)
  • The maximum tolerated dose (MTD) of Docetaxel-PNP [ Time Frame: up to 6 cycle ]
    Administration of docetaxel-PNP was well tolerated up 6mg/m² every 3weeks by heavily pretreated patients.
  • The recommended phase II dose of Docetaxel-PNP [ Time Frame: up to 6 cycle ]
    Futher phase Ⅱ Trials are recommended at this dose level
  • The maximum tolerated dose (MTD) of Docetaxel-PNP
  • The recommended phase II dose of Docetaxel-PNP
Complete list of historical versions of study NCT01103791 on ClinicalTrials.gov Archive Site
  • The Dose Limiting Toxicity (DLT) [ Time Frame: up to 6 cycle ]
  • The pharmacokinetics of Docetaxel-PNP on Day 1 of 1st cycle (AUC, CL, T1/2, Tmax, Cmax, Vdss) [ Time Frame: up to 6 cycle ]
  • Objective response rate [ Time Frame: up to 6 cycle ]
  • The Dose Limiting Toxicity (DLT)
  • The pharmacokinetics of Docetaxel-PNP on Day 1 of 1st cycle (AUC, CL, T1/2, Tmax, Cmax, Vdss)
  • Objective response rate
Not Provided
Not Provided
 
A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies
A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies
This is a phase I trial to determine the maximum tolerated dose and recommended phase II dose of docetaxel-PNP (polymeric nanoparticle formulation of docetaxel) and to evaluate the safety and pharmacokinetics of docetaxel-PNP in subjects with advanced solid malignancies.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Advanced Solid Malignancies
Drug: Docetaxel-PNP
Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
  • Experimental: Cohort 1
    Docetaxel-PNP 20mg/m2
    Intervention: Drug: Docetaxel-PNP
  • Experimental: Cohort 2
    Docetaxel-PNP 35mg/m2
    Intervention: Drug: Docetaxel-PNP
  • Experimental: Cohort 3
    Docetaxel-PNP 45mg/m2
    Intervention: Drug: Docetaxel-PNP
  • Experimental: Cohort 4
    Docetaxel-PNP 60mg/m2
    Intervention: Drug: Docetaxel-PNP
  • Experimental: Cohort 5
    Docetaxel-PNP 75mg/m2
    Intervention: Drug: Docetaxel-PNP
  • Experimental: Cohort 6
    Docetaxel-PNP 90mg/m2
    Intervention: Drug: Docetaxel-PNP
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
19
April 2012
September 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient ages more than 18 years old
  • Patient should voluntarily sign a written informed consent before study entry
  • Patient historically or cytologically confirmed diagnosis of advanced solid tumor and patient with measurable disease or evaluable disease by RECIST criteria
  • Progressive disease with development of new lesions or an increase in preexisting lesions or standard therapy in order to provide clinical benefit does not exist or is no longer effective
  • Previous anti-cancer therapies must be completed before 21days of first study dose and Patient must have recovered from any previous therapy
  • Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • Patient has a life expectancy of at least 3 months
  • Baseline studies for determining eligibility must be completed within 14 days of first study dose and patient has a adequate organ function including the following:

    • Hb ≥ 10g/dl
    • ANC ≥ 1.5 X 109/L
    • Platelet count ≥ 100 X 109/L
    • Serum total bilirubin ≤ 1.5 mg/dL
    • Serum AST and ALT ≤ 2.5 X UNL
    • Serum ALP ≤ 2.5ⅹUNL
    • Serum creatinine ≤ 1.5 X UNL

Exclusion Criteria:

  • Patient has had a major surgery except tumor ablation within 2 weeks before screening visit
  • Patient has a brain metastasis with neurologic symptom
  • Patient has a sensory neuropathy or motor neuropathy ≥ grade 2 by NCI-CTCAE
  • Patient has any serious concurrent disease such as:

Any medical or psychiatric condition that, in the opinion of the investigator, would prohibit the understanding and giving of informed consent Severe cardiovascular disease (e.g. ischemic heart disease requiring medication or myocardial infraction within the past six months, grade 3-4 congestive heart failure defined by the New York Heart Association criteria) Active un controlled infection.

  • Patient has hypersensitivity to the Investigational product or their excipients
  • Patient has participated in any other clinical trial within 4 weeks before screening visit
  • Woman is pregnant or breast feeding
  • Subjects who are of childbearing potential who do not use a medically acceptable method of birth control or do not agree to continue use of this method throughout the trial (screening, treatment period, and 3 weeks from the last done). A negative pregnancy test (urine or serum) should be documented within 14 days prior to initiation of trial medication for women of childbearing potential who have not been amenorrheic for at least 12 months prior to registration into the trial or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy). Medically acceptable methods include:

    • Barrier method with spermicide
    • Intrauterine device
    • Complete abstinence, etc.
  • Patient who has a history of resistance, intolerance, or no response to Docetaxel therapy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01103791
DOPNP101
Yes
Not Provided
Not Provided
Not Provided
Samyang Biopharmaceuticals Corporation
Samyang Biopharmaceuticals Corporation
Not Provided
Principal Investigator: Kyung Hae Jung, Ph. D. Asan Medical Center
Samyang Biopharmaceuticals Corporation
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP